We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+7.13%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$153M
AUM Growth
-$29.4M
Cap. Flow
-$39M
Cap. Flow %
-25.42%
Top 10 Hldgs %
96.84%
Holding
18
New
1
Increased
3
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$18.9M
2
SLN
Silence Therapeutics
SLN
+$13.4M
3
CMPX icon
Compass Therapeutics
CMPX
+$11.6M
4
SRZNW icon
Surrozen Inc Warrant
SRZNW
+$1.31M

Top Sells

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$25.2M
2
SWTX
SpringWorks Therapeutics
SWTX
+$19.4M
3
UTHR icon
United Therapeutics
UTHR
+$19.2M
4
GMED icon
Globus Medical
GMED
+$15.7M
5
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 90.18%
2 Financials 8.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNDM icon
1
Tandem Diabetes Care
TNDM
$1.17B
$45.3M 29.52%
300,664
-186,663
-38% -$25.2M
GMED icon
2
Globus Medical
GMED
$10.4B
$26.9M 17.58%
373,254
-215,846
-37% -$15.7M
SRZN icon
3
Surrozen
SRZN
$229M
$22.4M 14.58%
233,167
+166,500
+250% +$18.9M
SLN
4
Silence Therapeutics
SLN
$521M
$18.1M 11.82%
758,253
+579,466
+324% +$13.4M
UTHR icon
5
United Therapeutics
UTHR
$26.3B
$12.9M 8.43%
59,838
-98,000
-62% -$19.2M
CMPX icon
6
Compass Therapeutics
CMPX
$373M
$11.2M 7.28%
+3,500,000
New +$11.6M
RACB
7
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$2.93M 1.91%
300,000
– –
JYAC
8
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.93M 1.91%
300,000
– –
MSAC
9
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$2.92M 1.9%
300,000
– –
ARYE
10
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$2.91M 1.9%
300,000
– –
PANA
11
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$1.94M 1.27%
200,000
– –
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$1.59B
$1.48M 0.97%
150,000
– –
SRZNW icon
13
Surrozen Inc Warrant
SRZNW
$49.5K
$1.33M 0.87%
1,165,832
+832,499
+250% +$1.31M
CMAXW
14
DELISTED
CareMax, Inc. Warrant
CMAXW
$64K 0.04%
45,960
– –
MSACW
15
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$24K 0.02%
33,331
– –
CASI
16
DELISTED
CASI Pharmaceuticals
CASI
– –
-156,300
Closed -$1.86M
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
– –
-305,994
Closed -$19.4M
OLK
18
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
– –
-115,425
Closed -$2.8M

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Consonance Capital Management held 18 positions worth $153M, down 16% from $183M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Consonance Capital Management withdrew a net $39M in Q4 2021, closing 3 positions and reducing 3 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $19.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Financials.

Against the trend, Consonance Capital Management opened a new position in Compass Therapeutics worth $11.2M.

  • Consonance Capital Management's largest Q4 2021 buy was Compass Therapeutics: 3,500,000 shares worth $11.2M.
  • Consonance Capital Management added most to Surrozen in Q4 2021, an estimated $18.9M increase.
  • Consonance Capital Management's biggest Q4 2021 reduction was Tandem Diabetes Care, cutting an estimated $25.2M.
  • Consonance Capital Management fully exited SpringWorks Therapeutics in Q4 2021, selling an estimated $19.4M.
  • Consonance Capital Management's ten largest holdings make up 97% of its $153M portfolio in Q4 2021.
  • Consonance Capital Management opened 1 new position and closed 3 in Q4 2021.
  • Consonance Capital Management's portfolio value fell 16% quarter-over-quarter to $153M.

Based on Consonance Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.